Expert Video - What is a genetic mutation, a biomarker, and cytogenetic analysis in MDS?

Rafael Bejar, MD, PhD, Director of the MDS Center of Excellence at the Moores Cancer Center of the University of San Diego, explains what mutations in individual genes mean for the outlook with myelodysplastic syndromes (MDS). He also discusses the use of biomarker testing to monitor and predict MDS disease course and the importance of cytogenetic analysis to look for chromosomal abnormalities affecting MDS prognosis and treatment.

  • Share with family and friends:

Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.


This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.

This activity is supported by an educational grant from Acceleron Pharma, Bristol-Myers Squibb, Celgene Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals, and Takeda Oncology.

This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.